Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Amitriptyline 1.25mg/5ml oral solution
0403010B0AABGBG
|
Amitriptyline hydrochloride | Amitriptyline hydrochloride | Central Nervous System | No data available |
|
Amitriptyline 100mg/5ml oral solution
0403010B0AAA2A2
|
Amitriptyline hydrochloride | Amitriptyline hydrochloride | Central Nervous System | No data available |
|
Amitriptyline 10mg / Perphenazine 2mg tablets
0403010B0AAA9A9
|
Amitriptyline hydrochloride | Amitriptyline hydrochloride | Central Nervous System | No data available |
|
Amitriptyline 150mg/5ml oral solution
0403010B0AABFBF
|
Amitriptyline hydrochloride | Amitriptyline hydrochloride | Central Nervous System | No data available |
|
Amitriptyline 15mg/5ml oral solution
0403010B0AABEBE
|
Amitriptyline hydrochloride | Amitriptyline hydrochloride | Central Nervous System | No data available |
|
Amitriptyline 2.5mg/5ml oral solution
0403010B0AABBBB
|
Amitriptyline hydrochloride | Amitriptyline hydrochloride | Central Nervous System | No data available |
|
Amitriptyline 25mg / Perphenazine 2mg tablets
0403010B0AAA8A8
|
Amitriptyline hydrochloride | Amitriptyline hydrochloride | Central Nervous System | No data available |
|
Amitriptyline 25mg modified-release capsules
0403010B0AAAAAA
|
Amitriptyline hydrochloride | Amitriptyline hydrochloride | Central Nervous System | No data available |
|
Amitriptyline 25mg/5ml oral suspension
0403010B0AAA5A5
|
Amitriptyline hydrochloride | Amitriptyline hydrochloride | Central Nervous System | No data available |
|
Amitriptyline 50mg modified-release capsules
0403010B0AAABAB
|
Amitriptyline hydrochloride | Amitriptyline hydrochloride | Central Nervous System | No data available |
|
Amitriptyline 5mg/5ml oral liquid
0403010B0AABDBD
|
Amitriptyline hydrochloride | Amitriptyline hydrochloride | Central Nervous System | No data available |
|
Amitriptyline 75mg/5ml oral solution
0403010B0AAA1A1
|
Amitriptyline hydrochloride | Amitriptyline hydrochloride | Central Nervous System | No data available |
|
Amitriptyline 80mg/5ml oral solution
0403010B0AAA7A7
|
Amitriptyline hydrochloride | Amitriptyline hydrochloride | Central Nervous System | No data available |
|
Amobarbital 50mg tablets
0401030C0AAACAC
|
Amobarbital | Amobarbital | Central Nervous System | No data available |
|
Amoxapine 100mg tablets
0403010C0AAACAC
|
Amoxapine | Amoxapine | Central Nervous System | No data available |
|
Amoxapine 50mg tablets
0403010C0AAABAB
|
Amoxapine | Amoxapine | Central Nervous System | No data available |
|
Amphero XL 150mg capsules
0403040W0CBAAAE
|
Amphero | Venlafaxine | Central Nervous System | No data available |
|
Amphero XL 75mg capsules
0403040W0CBABAD
|
Amphero | Venlafaxine | Central Nervous System | No data available |
|
Amytal 50mg tablets
0401030C0BBACAC
|
Amytal | Amobarbital | Central Nervous System | No data available |
|
Anadin Extra soluble tablets
0407010W0BMABA0
|
Anadin Extra | Aspirin combined preparations | Central Nervous System | No data available |
|
Anadin Paracetamol 500mg tablets
0407010H0CNAAAM
|
Anadin (Paracetamol) | Paracetamol | Central Nervous System | No data available |
|
Anafranil 10mg capsules
0403010F0BBAAAA
|
Anafranil | Clomipramine hydrochloride | Central Nervous System | No data available |
|
Anafranil 25mg capsules
0403010F0BBABAB
|
Anafranil | Clomipramine hydrochloride | Central Nervous System | No data available |
|
Anafranil 25mg/2ml solution for injection ampoules
0403010F0BBAEAD
|
Anafranil | Clomipramine hydrochloride | Central Nervous System | No data available |
|
Anafranil 25mg/5ml syrup
0403010F0BBADAK
|
Anafranil | Clomipramine hydrochloride | Central Nervous System | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.